Shalby Ltd

- No significant capex is planned over the next 12 months for either the hospital or implant business, suggesting limited need for large fundraising. - The implant business's funding requirement is expected to be 30% to 40% of the EBITDA it generates going forward. - Management expects net debt to be slightly lower 12 months from now due to increased profitability and ramp-up in implant sales. - There is optimism about debt reduction as hospital business EBITDA grows and implant business funding needs reduce. - No specific plans for raising new debt or equity were mentioned in the call.

- No significant capex is planned over the next 12 months for the hospital or implant business. - Recent heavy investments made in infrastructure upgrades, high-end robotics, and diagnostics (including installation of new PET CT scan). - Planned addition of 2 more radiation oncology bunkers in Mohali and Delhi NCR within the next 12 to 18 months. - Bed addition of about 50 beds planned in Delhi NCR at an appropriate time. - Capex related to implant business (instruments and other equipment) largely incurred; minimal similar capex expected over next 2-3 years. - Future investments in technology and strategic upgrades, especially robotics, to continue on a strategic basis. - No aggressive capex plans on franchisee expansion; franchisee growth not prioritized currently.

- Hospital business expects 60% to 70% more work growth in existing hospitals over the next 2 years due to infrastructure upgrades including robotics and diagnostics. - Additional bed capacity available for ramp-up, e.g., 50+ beds in Delhi NCR region planned to be utilized at the right time. - ARPOB (Average Revenue Per Occupied Bed) expected to grow around 5%-6% historically; robotics and rate revisions by government/insurance to contribute to higher ARPOB. - Implant business showing strong revenue growth: 65% growth last year and similar in FY '26, with a large $35 billion global market opportunity and geographic expansion underway. - New product launches and regulatory approvals in multiple countries (Malaysia, Argentina, South Korea, Vietnam, Iran, etc.) expected to drive international sales growth over next 12-14 months. - Overall revenue growth expected to be supported by ramp-up in occupancy, outpatient/inpatient counts, implant sales, and higher realizations from new technology adoption.

- Hospital business aims to stabilize and grow EBITDA margins to 20% per unit, potentially reaching 23%-25% at 50% higher occupancy in coming quarters. - Expansion plans include ramping up existing hospital capacity by 60%-70% with investments in infrastructure, robotics, diagnostics, and clinical talent. - No significant capex expected in hospital or implant business over next 12 months; focus on operational ramp-up. - MedTech/implant business is transitioning from turnaround to structured growth with revenue more than doubling YoY and improving margins. - Implant business capacity issues largely resolved; regulatory challenges persist but targeted market expansions underway. - EBITDA breakeven achieved in MedTech; PAT breakeven expected in future but no specific guidance. - ARPOB expected to grow 5%-6% driven by rate revisions and robotics. - Net debt expected to reduce over next 12 months due to stronger EBITDA and lower capex needs.

The provided transcript from Shalby Limited's Q3 FY '26 earnings call does not explicitly mention details about the current or expected order book or pending orders. The discussion primarily focuses on: - Hospital occupancy, margin improvement, bed capacity, and profitability. - Implant business aspirations, regulatory and capacity challenges. - Expansion plans, including addition of beds and infrastructure upgrades. - Performance and challenges in different hospital units. - Supply chain, inventory planning, and financial outlook including debt trajectory. No specific quantitative data or commentary on the order book or pending orders is available in the transcript.